Tamtam Try Tamtam free
Weight Watchers logo

Weight Watchers account plan

Personalized weight management support

At a glance

Weight Watchers runs subscription weight-management programs and a U.S. GLP-1 telehealth clinic, with 2.3 million subscribers and about 3,500 employees.

WW International, Inc. (Weight Watchers), headquartered in New York, sells subscription weight-management programs combining community, nutrition, behavioral science, digital tools and coaching, and in the U.S. gives access to clinicians who can prescribe GLP-1 medications. It offers three tiers: Core and Core+ (Behavioral) and Med+ (Clinical), directly and through Weight Watchers for Business to employers and health plans. The company emerged from Chapter 11 on June 24, 2025; fiscal 2025 revenue was $347.1 million (June 25 to December 31) plus $363.6 million (December 29, 2024 to June 24, 2025). It had about 3,500 employees in nine countries at December 31, 2025, and 2.3 million subscribers at September 30, 2026. Stephen J. Bye became President and CEO on October 1, 2026.

Business units

Strategic priorities

Grow the higher-value tiers
Core+ and Med+ now generate roughly half of revenue; Clinical is expected at about 25% of full-year 2026 revenue, against about 16% in 2025.
Lower churn and longer lifetime value
CEO Stephen Bye wants to remove friction points in every customer journey, lower churn and keep investing in the app and emerging technology.
Ongoing guidance in a commoditized GLP-1 market
Bye sees GLP-1 access becoming commoditized and a gap in ongoing nutritional and behavioral support, which Core, Core+ and Med+ are designed to fill.
Clinical intake and pricing clarity
COO Jon Volkmann plans to match members to the right pathway using medical history, goals and insurance profile, with earlier cost transparency for medication.
Diversified marketing and partnerships
After Q1 awareness gains did not carry through the year, the company is building a more diversified marketing approach and exploring partnerships beyond Google Health, Sam's Club and LillyDirect.
Return to profitable growth in 2027
Bye aims to return the business to sustainable, profitable growth in 2027 with operating and fiscal discipline.

Latest results

In Q3 2026 (quarter ended September 30, 2026) revenue was $152.9 million, down 11.2%, as Behavioral Subscription Revenue fell 21.5% and Clinical rose 47.6%. End of Period subscribers fell 23.1% to 2,296.0 thousand, while monthly revenue per average subscriber rose 14.3% to $21.17. Operating income was $36.5 million and net income $15.1 million against a $57.5 million loss a year earlier; Adjusted EBITDA rose 21% to $51.7 million. Full-year 2026 guidance was narrowed to revenue of $625 million to $630 million and Adjusted EBITDA of $110 million to $115 million.

Investments and deals

App re-platforming and AI features
The app was relaunched in January 2026 on rebuilt infrastructure with an AI Body Scanner, AI-powered Food Tracker and Recipe Analyzer; capitalized software and website development was $18,899 thousand over nine months of 2026.
Debt reduction
Debt was cut from approximately $1.6 billion to $423.6 million; in May 2026 the company retired $14.6 million of principal at 68.5% of par and paid a $26.8 million excess-cash sweep in June.
Peoplehood asset acquisition
On August 6, 2025 the company acquired assets of Peoplehood, a wellness support platform, for $1.0 million in cash plus $1.0 million deferred.
Brand modernization
The company is modernizing the brand into "a bolder, more contemporary identity that is credible in medical solutions"; peak-season marketing raised Med+ awareness by 8 points to 30%.

Challenges and risks

Shrinking Behavioral base
Behavioral subscribers fell 25.9% in Q3 2026, and Core faces "multiyear ongoing secular headwinds" as consumers focus on medications.
GLP-1 competition
Telehealth providers, pharma, pharmacies, free apps and generative-AI tools compete for members, and medication access is becoming commoditized.
Clinical subscriber volatility
Clinical subscribers fell from 197.3 thousand at the end of June to 174.3 thousand at September 30, 2026 after compounded semaglutide plans came up for renewal and Q3 marketing was lower.
Costly debt and impairment risk
The term loan carries a weighted average rate of about 10.48%, and the Behavioral reporting unit and trade name were identified as at risk of impairment.
Leadership transition
Tara Comonte resigned in March 2026 and Stephen J. Bye started on October 1, 2026; the 10-Q warns the transition could slow "progress on key strategic initiatives".

What leadership says

“I'll be very clear. I believe this business is not living up to its potential.”

Stephen J. Bye, President and Chief Executive Officer · Q3 2026 earnings call, his first as CEO, November 5, 2026

“access to GLP-1 medication is becoming increasingly commoditized and new options are coming”

Stephen J. Bye, President and Chief Executive Officer · Q3 2026 earnings call, November 5, 2026

“remained focused on strengthening our two higher-value product offerings and proactively calibrating our spend across our portfolio”

Felicia DellaFortuna, Chief Financial Officer · Third Quarter 2026 results press release, November 5, 2026

“GLP-1 medications represent a permanent structural shift in how the world understands weight, obesity, and metabolic health.”

Tara M. Comonte, former President and Chief Executive Officer · Q4 and full year 2025 earnings call, March 16, 2026

Where a supplier can help

Retention and lifecycle marketing
Lowering churn and extending lifetime value is a stated CEO priority; customer engagement, personalization and subscription analytics vendors fit directly.
Diversified acquisition channels
Management is building a more diversified marketing approach and exploring new partnerships; performance marketing, affiliate and retail-partner platforms address this priority.
Clinical operations tooling
Better clinical intake, prior authorization navigation and earlier cost transparency are COO priorities; telehealth workflow, eligibility and benefits verification tools can support them.
Employer and health plan channel
Weight Watchers for Business and the RxFlexFund sell to employers and payers; benefits platforms and brokers can help scale this still-small channel.
Workflow automation
Adjusted gross margin gains came from workflow automation; automation and AI vendors can help hold margins as the mix shifts to labor-heavier Clinical.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Weight Watchers?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Weight Watchers

What does Weight Watchers do?

Weight Watchers sells subscription weight-management programs (Core and Core+) built on nutrition, behavioral science, coaching and community, and in the U.S. a telehealth membership (Med+) where clinicians can prescribe GLP-1 medications.

What is Weight Watchers' revenue?

Q3 2026 revenue was $152.9 million, and the company guides to $625 million to $630 million for fiscal 2026. Fiscal 2025 revenue was split into $363.6 million before and $347.1 million after its emergence from Chapter 11.

How many employees does Weight Watchers have?

About 3,500 employees in nine countries at December 31, 2025, a majority of them part-time.

Who leads Weight Watchers?

Stephen J. Bye has been President and CEO since October 1, 2026, with Felicia DellaFortuna as CFO and Jonathan Volkmann as COO.

What is Weight Watchers' strategy for the GLP-1 era?

It positions itself as the support system around GLP-1 medications, growing Med+ and Core+, lowering churn, improving the app and returning to profitable growth in 2027.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)